Premium
Increased peripheral blood T‐cell apoptosis and decreased Bcl‐2 in chronic obstructive pulmonary disease
Author(s) -
Hodge Sandra,
Hodge Greg,
Holmes Mark,
Reynolds Paul N
Publication year - 2005
Publication title -
immunology and cell biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.999
H-Index - 104
eISSN - 1440-1711
pISSN - 0818-9641
DOI - 10.1111/j.1440-1711.2005.01317.x
Subject(s) - copd , apoptosis , medicine , immunology , annexin , cd8 , cytokine , immune system , flow cytometry , inflammation , endocrinology , biology , biochemistry
Chronic obstructive pulmonary disease (COPD) is an inflammatory airway disease, usually associated with cigarette smoking. Stimulated peripheral blood T cells from patients with COPD have an increased propensity to undergo apoptosis. The mitochondrial apoptotic pathway is regulated by pro‐apoptotic proteins (including p53 and Bax) as well as anti‐apoptotic proteins (e.g. Bcl‐2) and cytokines (IL‐2, IL‐4 and IL‐7). We hypothesized that alterations in expression of these apoptosis‐related proteins, cytokines and cytokine receptors may be important in determining the susceptibility of T cells to undergoing apoptosis in COPD. We further hypothesized that inhaled corticosteroids (GCS) contribute to the increased rates of T‐cell apoptosis observed in COPD. The process of apoptosis (assessed by Annexin V and ssDNA staining), as well as Bcl‐2, Bax, p53, IL‐2, IL‐4 and receptors IL‐7R, IL‐4R and IL‐2Rγ were investigated in PHA‐stimulated peripheral blood‐derived T cells, using flow cytometry. Fifteen patients with COPD receiving inhaled GCS (four of who received additional prednisolone), eight patients with COPD receiving symptom control medication, and 16 control subjects were studied. T cells (CD4 + and CD8 + ) from GCS‐treated COPD patients showed an increased propensity to undergo apoptosis, associated with significantly decreased Bcl‐2 and IL‐7 receptor expression. No significant differences were observed for the COPD patients who were receiving symptom control medication. These findings may suggest a negative peripheral effect of inhaled GCS on the immune system in COPD, although the clinical significance of these effects remains uncertain.